10 Best Performing NASDAQ Stocks According to Wall Street Analysts
On April 28, Tom Lee of Fundstrat joined CNBC's 'Power Lunch' to discuss the outlook for equity markets.
Climb Bio Inc. (CLYM)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 11,300,939 | $77,411,432 | +1% | 0.82% |
| 2. | BioImpact Capital Mpm Capital | 2,593,439 | $17,765,057 | -3% | 1.37% |
| 3. | Braidwell LP Alex Karnal | 1,529,675 | $10,478,274 | 0.35% | |
| 4. | Great Point Partners Jeffrey Jay And David Kroin | 1,334,130 | $9,138,791 | +37% | 2.1% |
| 5. | Millennium Management Israel Englander | 1,276,260 | $8,742,381 | +331% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.50 | 7,111 | $24,888.50 | 3,403,429 | 2026-01-05 | Filing | |
| $2.86 | 101,462 | $290,181.32 | 3,396,318 | 2025-12-12 | Filing | |
| $2.18 | 213,099 | $464,555.82 | 3,294,856 | 2025-12-11 | Filing | |
| $3.84 | 1,059,375 | $4,068,000.00 | 2,866,375 | 2024-06-27 | Filing | |
| $3.84 | 11,949,171 | $45,884,816.64 | 23,521,757 | 2024-06-27 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.01 | 16,313 | $114,288.88 | 154,657 | 2026-02-26 | Filing | |
| $7.00 | 33,687 | $235,963.96 | 170,970 | 2026-02-25 | Filing | |
| $5.81 | 10,000 | $58,141.00 | 204,657 | 2026-02-13 | Filing | |
| $5.23 | 90,000 | $470,988.00 | 214,657 | 2026-02-12 | Filing | |
| $1.22 | 20,618 | $25,153.96 | 48,132 | 2025-06-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,178,659 | $8,073,814 | 0% | |
| 2. | 700,000 | $4,795,000 | 0.25% | |
| 3. | 420,517 | $2,880,541 | 0.32% | |
| 4. | 401,649 | $2,751,296 | 0% | |
| 5. | 387,403 | $2,653,711 | 0% |
News See All
Why Climb Bio (CLYM) is One of the Best Performing Small Cap Stocks So Far in 2026
Climb Bio Inc (NASDAQ:CLYM) is one of the best performing small cap stocks so far in 2026. Oppenheimer lifted the price target on Climb Bio Inc (NASDAQ:CLYM) to $18 from $10 on April 12, maintaining ...
10 Best Performing Small Cap Stocks So Far in 2026
Talking about the hiccup in tech, she was of the view that we are going to go through this over and over again, which includes worries about whether or not spending can keep up.
10 Tiny Stocks That Are On Fire Right Now
On April 16, Fundstrat’s Tom Lee joined 'Closing Bell' to argue that the stock market is currently in a stronger position than it was earlier in the year when it reached all-time highs.
8 Must-Buy Small Cap Stocks to Buy
After many years of large capitalization companies dominating the US equities market, time is ripe for rotation.
H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio’s (CLYM) Budoprutug Across Clinical Tracks
Climb Bio Inc. (NASDAQ:CLYM) is one of the best biotech penny stocks to buy according to analysts. On December 18, H.C.
10 Best Biotech Penny Stocks to Buy According to Analysts
On December 24, Jared Holz of Mizuho joined 'Power Lunch' on CNBC to talk about how to play biotech moving into 2026.
William Blair Initiates Coverage of Climb Bio (CLYM) with Outperform Rating on Autoimmune Drug Potential
Climb Bio Inc. (NASDAQ:CLYM) is one of the best stocks under $3 to invest in.
10 Best Stocks Under $3 to Invest In
On October 16, Victoria Greene, Chief Investment Officer of G Squared Private Wealth Management, appeared on CNBC to state that small caps demonstrate lasting strength.